FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200487208> ?p ?o ?g. }

• W4200487208 endingPage "S789" @default.
• W4200487208 startingPage "S789" @default.
• W4200487208 abstract "Abstract Background Data on the efficacy and tolerability of latent tuberculosis infection (LTBI) treatment in cancer patients receiving checkpoint inhibitor immunotherapy (CPI) is limited. We sought to assess LTBI therapy and its adverse events and outcomes in patients treated with CPI. Methods We performed a retrospective cohort study at MD Anderson Cancer Center of adult patients, between April 2016 and May 2021, who were receiving CPI and were diagnosed with LTBI based on positive T-SPOT TB test. We then compared those patients treated with isoniazid (INH) 5mg/kg daily versus those that did not receive INH therapy. Results We identified 35 patients treated with CPI who had a diagnosis of LTBI. Patients were divided into 2 groups: CPI alone (23 patients, 65.7%) and CPI+INH (12 patients, 34.3%). The majority of patients in both groups had renal cell carcinoma (34.3%) and melanoma (17.1%). Nivolumab as monotherapy was the most commonly used CPI agent in both groups (37.1%), whereas nivolumab and ipilimumab combination was mainly used in the CPI group (34.7%) compared to CPI+INH group (8.3%). In the CPI+INH group, 7 patients (58.3%) developed moderate to severe hepatoxicity that led to discontinuation of INH and CPI therapy versus none in the CPI group (p= 0.001). There was no statistically significant difference in the alanine aminotransferase (ALT) at baseline between both groups (p=0.117), whereas the median ALT level was significantly higher during CPI+INH therapy compared to CPI alone (135 U/L vs 24 U/L respectively, p=0.025. Furthermore, immune-related adverse events were reported in a total of 12 of 35 patients (34.2%). None of the patients in either group developed tuberculosis reactivation during a follow up period of up to 1148 days. Conclusion Our data suggest that latent tuberculosis reactivation is rare in cancer patients on CPI immunotherapy. Hepatotoxicity remains a concern in this patient population with LTBI treated with CPI and INH. With the widespread use of CPI, close laboratory and clinical monitoring is required to avoid life-threatening drug-induced liver injury and interruption of LTBI therapy and immunotherapy. Further clinical studies are warranted to determine the optimal management of LTBI during CPI therapy. Disclosures Pablo C. Okhuysen, MD, FACP, FIDSA, Deinove Pharmaceuticals (Grant/Research Support)Ferring Pharmaceuticals (Consultant)Melinta Therapeutics (Grant/Research Support)Merck & Co. (Grant/Research Support)Napo Pharmaceuticals (Consultant, Scientific Research Study Investigator, Research Grant or Support)Singulex (Consultant)Summit Therapeutics (Grant/Research Support) Dimitrios P. Kontoyiannis, MD, Astellas (Consultant)Cidara Therapeutics (Advisor or Review Panel member)Gilead Sciences (Consultant, Grant/Research Support, Other Financial or Material Support, Honoraria)" @default.
• W4200487208 created "2021-12-31" @default.
• W4200487208 creator A5013302356 @default.
• W4200487208 creator A5022649229 @default.
• W4200487208 creator A5022721148 @default.
• W4200487208 creator A5032568166 @default.
• W4200487208 creator A5033841614 @default.
• W4200487208 creator A5041039527 @default.
• W4200487208 creator A5053146342 @default.
• W4200487208 creator A5055182697 @default.
• W4200487208 creator A5067777914 @default.
• W4200487208 creator A5080586874 @default.
• W4200487208 creator A5083755423 @default.
• W4200487208 date "2021-11-01" @default.
• W4200487208 modified "2023-10-16" @default.
• W4200487208 title "1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy" @default.
• W4200487208 doi "https://doi.org/10.1093/ofid/ofab466.1602" @default.
• W4200487208 hasPublicationYear "2021" @default.
• W4200487208 type Work @default.
• W4200487208 citedByCount "0" @default.
• W4200487208 crossrefType "journal-article" @default.
• W4200487208 hasAuthorship W4200487208A5013302356 @default.
• W4200487208 hasAuthorship W4200487208A5022649229 @default.
• W4200487208 hasAuthorship W4200487208A5022721148 @default.
• W4200487208 hasAuthorship W4200487208A5032568166 @default.
• W4200487208 hasAuthorship W4200487208A5033841614 @default.
• W4200487208 hasAuthorship W4200487208A5041039527 @default.
• W4200487208 hasAuthorship W4200487208A5053146342 @default.
• W4200487208 hasAuthorship W4200487208A5055182697 @default.
• W4200487208 hasAuthorship W4200487208A5067777914 @default.
• W4200487208 hasAuthorship W4200487208A5080586874 @default.
• W4200487208 hasAuthorship W4200487208A5083755423 @default.
• W4200487208 hasBestOaLocation W42004872081 @default.
• W4200487208 hasConcept C121608353 @default.
• W4200487208 hasConcept C126322002 @default.
• W4200487208 hasConcept C142724271 @default.
• W4200487208 hasConcept C143998085 @default.
• W4200487208 hasConcept C197934379 @default.
• W4200487208 hasConcept C2776967927 @default.
• W4200487208 hasConcept C2776999253 @default.
• W4200487208 hasConcept C2777701055 @default.
• W4200487208 hasConcept C2777975735 @default.
• W4200487208 hasConcept C2778375690 @default.
• W4200487208 hasConcept C2778715236 @default.
• W4200487208 hasConcept C2779806340 @default.
• W4200487208 hasConcept C2780030458 @default.
• W4200487208 hasConcept C2781069245 @default.
• W4200487208 hasConcept C2781433595 @default.
• W4200487208 hasConcept C71924100 @default.
• W4200487208 hasConceptScore W4200487208C121608353 @default.
• W4200487208 hasConceptScore W4200487208C126322002 @default.
• W4200487208 hasConceptScore W4200487208C142724271 @default.
• W4200487208 hasConceptScore W4200487208C143998085 @default.
• W4200487208 hasConceptScore W4200487208C197934379 @default.
• W4200487208 hasConceptScore W4200487208C2776967927 @default.
• W4200487208 hasConceptScore W4200487208C2776999253 @default.
• W4200487208 hasConceptScore W4200487208C2777701055 @default.
• W4200487208 hasConceptScore W4200487208C2777975735 @default.
• W4200487208 hasConceptScore W4200487208C2778375690 @default.
• W4200487208 hasConceptScore W4200487208C2778715236 @default.
• W4200487208 hasConceptScore W4200487208C2779806340 @default.
• W4200487208 hasConceptScore W4200487208C2780030458 @default.
• W4200487208 hasConceptScore W4200487208C2781069245 @default.
• W4200487208 hasConceptScore W4200487208C2781433595 @default.
• W4200487208 hasConceptScore W4200487208C71924100 @default.
• W4200487208 hasIssue "Supplement_1" @default.
• W4200487208 hasLocation W42004872081 @default.
• W4200487208 hasLocation W42004872082 @default.
• W4200487208 hasOpenAccess W4200487208 @default.
• W4200487208 hasPrimaryLocation W42004872081 @default.
• W4200487208 hasRelatedWork W2475687906 @default.
• W4200487208 hasRelatedWork W2534538480 @default.
• W4200487208 hasRelatedWork W2947988614 @default.
• W4200487208 hasRelatedWork W2984732343 @default.
• W4200487208 hasRelatedWork W3005150264 @default.
• W4200487208 hasRelatedWork W3028884037 @default.
• W4200487208 hasRelatedWork W3032186543 @default.
• W4200487208 hasRelatedWork W3064391356 @default.
• W4200487208 hasRelatedWork W3118891956 @default.
• W4200487208 hasRelatedWork W4200487208 @default.
• W4200487208 hasVolume "8" @default.
• W4200487208 isParatext "false" @default.
• W4200487208 isRetracted "false" @default.
• W4200487208 workType "article" @default.